SCHEMBL14082429

SCHEMBL14082429

Cc1ccnc(-c2ccc(C(=O)Nc3ccc(Cl)cc3Cl)cc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 2/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.60
▸ NPC1 O15118 3/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ POLB P06746 2/20 0.49
▸ THRB P10828 1/20 0.48
▸ CNR1 P21554 1/20 0.48
▸ PIK3CG P48736 1/20 0.48
▸ KMT2A Q03164 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ HSP90AA1 P07900 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ APOBEC3G Q9HC16 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ GRM4 Q14833 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14082399 0.87 NPC1 (0.63) NPSR1NPC1RAB9AKMT2AMEN1
SCHEMBL14082233 0.83 KDM4E (0.70) RXFP1KDM4ENPSR1NPC1RAB9A
SCHEMBL14082683 0.83 RXFP1 (0.56) RXFP1KDM4ENPSR1NPC1RAB9A
SCHEMBL14082419 0.83 NPC1 (0.61) NPSR1NPC1RAB9AMAPTALDH1A1
SCHEMBL14082420 0.82 NPC1 (0.60) NPC1RAB9APOLBCNR1KMT2A
SCHEMBL14082396 0.81 KCNK3 (0.60) NPC1RAB9ACNR1KMT2AMEN1
SCHEMBL14082457 0.81 KMT2A (0.70) RXFP1KDM4ENPC1RAB9APOLB
SCHEMBL14252940 0.80 MEN1 (0.62) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL14082359 0.78 NPC1 (0.71) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL14082392 0.78 KCNMA1 (0.56) NPC1RAB9APOLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200524-A1 Amide compounds as ion channel ligands and uses thereof KELLY MICHAEL G 2008-08-21 — — US disclosed
US-20080200524-A1 Amide compounds as ion channel ligands and uses thereof KELLY MICHAEL G 2008-08-21 — — US disclosed
US-7338950-B2 Amide compounds as ion channel ligands and uses thereof RENOVIS, INC. (US) 2008-03-04 — — US disclosed
US-7338950-B2 Amide compounds as ion channel ligands and uses thereof RENOVIS, INC. (US) 2008-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200524-A1 Amide compounds as ion channel ligands and uses thereof TRPV1, TRPA1, TRPV2 RXFP1 1053/4885KDM4E 4231/4885NPSR1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback